Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA

Rougier, Philippe; Raoul, Jean-Luc; Laethem, Jean Luc Van; Peeters, Marc; Husseini, F.; Brézault, Catherine; Cals, L.; Vedovato, Jean-Claude; Mueser, M.

doi:10.1200/jco.2004.22.90140.3513

Cited by 44 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An improved RR will hopefully result in even more curative intended resections. Compared to historical data, addition of antibodies to chemotherapy has increased the resection rate (Rougier et al, 2004;Folprecht et al, 2006;Andre et al, 2007), but presently it is not known for sure whether the higher resection rate is caused by more effective therapy or simply a matter of selection and more experienced surgeons. In an excellent review (Folprecht et al, 2005), it was found that 24-54% of patients with non-resectable liver metastases became resectable following chemotherapy, compared with 1-26% of patients in trials that included non-selected patients with mCRC.…”

Section: Surgery and Antibody Therapymentioning

confidence: 99%

“…Several small and preliminary reported phase II trials (Rougier et al, 2004;Dittrich et al, 2006;Folprecht et al, 2006;Andre et al, 2007) have shown a promising activity for chemotherapy-Cx combinations, but there are not yet mature and reliable data available from phase III studies. In these single-arm phase II studies, combinations with irinotecan-or oxaliplatin-based chemotherapy are well tolerated and active with RR ranging from 45 to 81% and OS ranging from 23 months to more than 30 months (Table 4).…”

Section: First-line Therapymentioning

confidence: 99%

“…In head and neck cancer, a small study with eight patients (Harari et al, 2003) receiving elective neck dissection after curative intended radiotherapy in combination with Cx, the length of hospital stay was not prolonged and no postoperative complications was found. In phase II studies in mCRC, a number of patients had R0 liver-resection after neo-adjuvant therapy without extra comlications reported (Rougier et al, 2004;Tabernero et al, 2004;Folprecht et al, 2006).…”

Section: Surgery and Antibody Therapymentioning

confidence: 99%

See 2 more Smart Citations

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

Section: Surgery and Antibody Therapymentioning

confidence: 99%

Section: First-line Therapymentioning

confidence: 99%

Section: Surgery and Antibody Therapymentioning

confidence: 99%

See 1 more Smart Citation

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…Cetuximab was subsequently investigated first-line in combination with irinotecan/infusional 5-FU/FA (Rougier et al, 2004;Folprecht et al, 2006). Initial results showed these combinations to be safe with promising activity.…”

Section: Cetuximabmentioning

confidence: 99%

Management of advanced colorectal cancer: state of the art

Saunders

Iveson

2006

Br J Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.

show abstract

“…Competitive binding of cetuximab to EGFR prevents ligand-induced tyrosine kinase activation and induces receptor downregulation. In clinical trials, cetuximab is active in colorectal cancer (Rosenberg et al, 2002;Cunningham et al, 2004;Folprecht et al, 2004;Lenz et al, 2004;Rougier et al, 2004;Saltz et al, 2004) and in concomitant treatment with radiotherapy in head and neck cancer (Bonner et al, 2006). Upregulation of cell-surface EGFR by bortezomib was indicated in earlier studies and recently reported in squamous-cell cancer lines (Lorch et al, 2007).…”

mentioning

confidence: 96%

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

et al. 2009

View full text Add to dashboard Cite

Bortezomib inhibits nuclear factor-kB (NF-kB). Cetuximab is a chimeric mouse -human antibody targeted against epidermal growth factor receptor (EGFR). We hypothesised that concomitant blockade of NF-kB and EGFR signalling would overcome EGFR-mediated resistance to single-agent bortezomib and induce apoptosis through two molecular pathways. The aim of this phase I trial was to establish the maximum tolerated dose (MTD) for bortezomib plus cetuximab in patients with EGFR-expressing epithelial tumours. The 21-day treatment cycle consisted of bortezomib administered on days 1 and 8 through dose escalation (1.3 -2 mg m À2 ). Cetuximab was delivered at a dose of 250 mg m À2 on days 1, 8 and 15 (400 mg m À2 day 1 cycle 1). A total of 37 patients were enroled and given a total 91 cycles. No grade X3 haematological toxicity was noted. Non-hematological grade X3 toxicities included fatigue (22% of patients), dyspnoea (16%) and infection (11%). The MTD was not reached at the highest tested bortezomib dose (2.0 mg m À2 ). Efficacy outcomes included disease progression in 21 patients (56.7%) and stable disease (SD) at 6 weeks in 16 patients (43.3%). Five of the six patients with SD at 12 weeks were diagnosed with cancers of the lungs or head and neck. This combination therapy was moderately effective in extensively pretreated patients with non-small cell lung or head and neck cancers and warrants further investigation.

show abstract

Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA

Cited by 44 publications

References 0 publications

Current role of antibody therapy in patients with metastatic colorectal cancer

Current role of antibody therapy in patients with metastatic colorectal cancer

Management of advanced colorectal cancer: state of the art

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

Contact Info

Product

Resources

About